BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33826763)

  • 1. Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.
    Crosier S; Hicks D; Schwalbe EC; Williamson D; Leigh Nicholson S; Smith A; Lindsey JC; Michalski A; Pizer B; Bailey S; Bown N; Cuthbert G; Wharton SB; Jacques TS; Joshi A; Clifford SC
    Neuropathol Appl Neurobiol; 2021 Oct; 47(6):736-747. PubMed ID: 33826763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
    Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
    Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
    Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
    Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
    Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 11. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the genomic complexity underlying medulloblastoma.
    Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
    Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes.
    Hicks D; Rafiee G; Schwalbe EC; Howell CI; Lindsey JC; Hill RM; Smith AJ; Adidharma P; Steel C; Richardson S; Pease L; Danilenko M; Crosier S; Joshi A; Wharton SB; Jacques TS; Pizer B; Michalski A; Williamson D; Bailey S; Clifford SC
    Neuropathol Appl Neurobiol; 2021 Feb; 47(2):236-250. PubMed ID: 32779246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
    Thompson EM; Hielscher T; Bouffet E; Remke M; Luu B; Gururangan S; McLendon RE; Bigner DD; Lipp ES; Perreault S; Cho YJ; Grant G; Kim SK; Lee JY; Rao AAN; Giannini C; Li KKW; Ng HK; Yao Y; Kumabe T; Tominaga T; Grajkowska WA; Perek-Polnik M; Low DCY; Seow WT; Chang KTE; Mora J; Pollack IF; Hamilton RL; Leary S; Moore AS; Ingram WJ; Hallahan AR; Jouvet A; Fèvre-Montange M; Vasiljevic A; Faure-Conter C; Shofuda T; Kagawa N; Hashimoto N; Jabado N; Weil AG; Gayden T; Wataya T; Shalaby T; Grotzer M; Zitterbart K; Sterba J; Kren L; Hortobágyi T; Klekner A; László B; Pócza T; Hauser P; Schüller U; Jung S; Jang WY; French PJ; Kros JM; van Veelen MC; Massimi L; Leonard JR; Rubin JB; Vibhakar R; Chambless LB; Cooper MK; Thompson RC; Faria CC; Carvalho A; Nunes S; Pimentel J; Fan X; Muraszko KM; López-Aguilar E; Lyden D; Garzia L; Shih DJH; Kijima N; Schneider C; Adamski J; Northcott PA; Kool M; Jones DTW; Chan JA; Nikolic A; Garre ML; Van Meir EG; Osuka S; Olson JJ; Jahangiri A; Castro BA; Gupta N; Weiss WA; Moxon-Emre I; Mabbott DJ; Lassaletta A; Hawkins CE; Tabori U; Drake J; Kulkarni A; Dirks P; Rutka JT; Korshunov A; Pfister SM; Packer RJ; Ramaswamy V; Taylor MD
    Lancet Oncol; 2016 Apr; 17(4):484-495. PubMed ID: 26976201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
    Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
    Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-495 is a Predictive Biomarker that Downregulates GFI1 Expression in Medulloblastoma.
    Wang C; Yun Z; Zhao T; Liu X; Ma X
    Cell Physiol Biochem; 2015; 36(4):1430-9. PubMed ID: 26160036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
    Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medulloblastoma genomics in the modern molecular era.
    Kumar R; Liu APY; Northcott PA
    Brain Pathol; 2020 May; 30(3):679-690. PubMed ID: 31799776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.